487 related articles for article (PubMed ID: 25552476)
1. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
2. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
3. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Evid Based Complement Alternat Med; 2014; 2014():236310. PubMed ID: 24955100
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
[TBL] [Abstract][Full Text] [Related]
7. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
Schad F; Axtner J; Kröz M; Matthes H; Steele ML
Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
Felenda JE; Turek C; Stintzing FC
J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
[TBL] [Abstract][Full Text] [Related]
9. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Evid Based Complement Alternat Med; 2014; 2014():724258. PubMed ID: 24672577
[TBL] [Abstract][Full Text] [Related]
10. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
Bar-Sela G; Gershony A; Haim N
Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
Melzer J; Iten F; Hostanska K; Saller R
Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
[TBL] [Abstract][Full Text] [Related]
12. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
13. Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations.
Zuzak TJ; Rist L; Eggenschwiler J; Grotzer MA; Viviani A
Anticancer Res; 2006; 26(5A):3485-92. PubMed ID: 17094471
[TBL] [Abstract][Full Text] [Related]
14. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy.
Kirsch A; Hajto T
J Altern Complement Med; 2011 Oct; 17(10):973-9. PubMed ID: 22010781
[TBL] [Abstract][Full Text] [Related]
15. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.
Kienle GS; Grugel R; Kiene H
BMC Complement Altern Med; 2011 Aug; 11():72. PubMed ID: 21871125
[TBL] [Abstract][Full Text] [Related]
16. Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study.
Schläppi M; Ewald C; Kuehn JJ; Weinert T; Huber R
Integr Cancer Ther; 2017 Dec; 16(4):479-484. PubMed ID: 27387685
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.
Mabed M; El-Helw L; Shamaa S
Br J Cancer; 2004 Jan; 90(1):65-9. PubMed ID: 14710208
[TBL] [Abstract][Full Text] [Related]
18. [Immunostimulatory properties of mistletoe extracts and their application in oncology].
Wrotek S; Skawiński R; Kozak W
Postepy Hig Med Dosw (Online); 2014 Oct; 68():1216-24. PubMed ID: 25380204
[TBL] [Abstract][Full Text] [Related]
19. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
[TBL] [Abstract][Full Text] [Related]
20. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series.
Gardin NE
Phytother Res; 2009 Mar; 23(3):407-11. PubMed ID: 19003944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
